H. Lundbeck A/S

BATS-CHIXE:HLUNBC Stock Report

Market Cap: DKK 42.5b

H. Lundbeck Valuation

Is HLUNBC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HLUNBC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLUNBC (DKK46.74) is trading below our estimate of fair value (DKK197.25)

Significantly Below Fair Value: HLUNBC is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLUNBC?

Other financial metrics that can be useful for relative valuation.

HLUNBC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA7.6x
PEG Ratio1.7x

Price to Earnings Ratio vs Peers

How does HLUNBC's PE Ratio compare to its peers?

The above table shows the PE ratio for HLUNBC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average25.8x
HIK Hikma Pharmaceuticals
19.7x13.1%UK£4.2b
GSK GSK
15.5x14.3%UK£62.7b
AZN AstraZeneca
37.5x16.4%UK£180.7b
ANCR Animalcare Group
30.5x15.8%UK£141.3m
HLUNBC H. Lundbeck
16.9x10.0%DKK 42.5b

Price-To-Earnings vs Peers: HLUNBC is good value based on its Price-To-Earnings Ratio (16.9x) compared to the peer average (25.8x).

Price to Earnings Ratio vs Industry

How does HLUNBC's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a16.3%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: HLUNBC is good value based on its Price-To-Earnings Ratio (16.9x) compared to the European Pharmaceuticals industry average (23.4x).

Price to Earnings Ratio vs Fair Ratio

What is HLUNBC's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLUNBC PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio16.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate HLUNBC's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HLUNBC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
DKK 46.29
0%
12.5%DKK 57.00DKK 35.00n/a12
Sep ’25n/a
DKK 45.54
0%
12.0%DKK 57.00DKK 35.00n/a12
Aug ’25n/a
DKK 40.88
0%
12.5%DKK 55.00DKK 35.00n/a12
Jul ’25n/a
DKK 39.96
0%
10.9%DKK 51.00DKK 35.00n/a12
Jun ’25n/a
DKK 39.96
0%
10.9%DKK 51.00DKK 35.00n/a12
May ’25n/a
DKK 38.71
0%
12.3%DKK 50.00DKK 33.00n/a12
Apr ’25n/a
DKK 38.79
0%
12.2%DKK 50.00DKK 33.00n/a12
Mar ’25n/a
DKK 38.35
0%
12.5%DKK 50.00DKK 33.00n/a13
Feb ’25n/a
DKK 38.27
0%
11.0%DKK 48.00DKK 33.00n/a13
Jan ’25n/a
DKK 38.58
0%
10.4%DKK 48.00DKK 33.00n/a13
Dec ’24n/a
DKK 38.79
0%
10.8%DKK 48.00DKK 32.00n/a12
Nov ’24n/a
DKK 39.05
0%
11.1%DKK 47.00DKK 32.00n/a11
Oct ’24n/a
DKK 37.77
0%
11.0%DKK 47.00DKK 32.00n/a11
Sep ’24n/a
DKK 37.38
0%
12.0%DKK 47.00DKK 30.00n/a12
Aug ’24n/a
DKK 37.13
0%
10.8%DKK 44.00DKK 30.00n/a12
Jul ’24DKK 32.06
DKK 36.88
+15.0%
12.5%DKK 44.00DKK 30.00n/a12
Jun ’24DKK 36.50
DKK 36.88
+1.0%
12.5%DKK 44.00DKK 30.00n/a12
May ’24DKK 35.86
DKK 34.63
-3.4%
15.6%DKK 44.00DKK 30.00n/a12
Apr ’24n/a
DKK 33.71
0%
14.3%DKK 42.50DKK 27.00n/a12
Mar ’24n/a
DKK 33.42
0%
14.2%DKK 42.50DKK 27.00n/a13
Feb ’24n/a
DKK 33.19
0%
15.2%DKK 43.00DKK 27.00n/a13
Jan ’24DKK 26.07
DKK 35.27
+35.3%
18.6%DKK 46.00DKK 27.00n/a13
Dec ’23DKK 26.32
DKK 36.19
+37.5%
16.7%DKK 46.00DKK 27.00n/a13
Nov ’23DKK 28.23
DKK 37.65
+33.4%
15.5%DKK 46.00DKK 27.00n/a13
Oct ’23DKK 24.80
DKK 39.27
+58.4%
11.8%DKK 46.00DKK 31.00n/a13
Sep ’23DKK 28.43
DKK 39.89
+40.3%
11.6%DKK 46.00DKK 32.60n/a13

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y